Avastin

Avastin, also known as bevacizumab, is a biologic therapy designed to inhibit the growth of abnormal blood vessels in the body. It works by targeting a protein called vascular endothelial growth factor (VEGF), which is involved in the formation of new blood vessels. By blocking VEGF, Avastin can slow the development of blood supply to abnormal or cancerous cells, potentially limiting their growth and spread.
This therapy has been utilized in the management of various cancers, including colorectal, lung, kidney, and certain types of brain tumors. It is typically delivered through intravenous infusion under medical supervision, allowing the active agent to circulate throughout the body. Treatment schedules may vary depending on the condition being addressed and the patient’s overall health.
Common effects associated with Avastin can include high blood pressure, fatigue, headache, and mild digestive disturbances. Rarely, it may cause more serious complications, such as bleeding, clot formation, or impaired wound healing, which require close monitoring by healthcare professionals. Regular assessments, including blood tests and imaging studies, are often conducted to track response and detect potential side effects early.
Because of its targeted mechanism, Avastin is frequently combined with other therapies to enhance overall effectiveness. Decisions regarding its use consider factors such as the specific type of disease, prior treatments, and individual patient characteristics. Ongoing research continues to explore new applications and strategies to maximize the benefits of Avastin while minimizing risks, making it a key component in modern targeted therapy approaches.